High levels of genomic aberrations in serous ovarian cancers are associated with better survival

Files

hdl_93479.pdf (587.3 KB)
  (Published version)

Date

2013

Authors

Baumbusch, L.
Helland, Å.
Wang, Y.
Liestøl, K.
Schaner, M.
Holm, R.
Etemadmoghadam, D.
Alsop, K.
Brown, P.
Australian Ovarian Cancer Study Group,

Editors

Bishop, A.

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

PLoS ONE, 2013; 8(1):e54356-1-e54356-8

Statement of Responsibility

Lars O. Baumbusch, Åslaug Helland, Yun Wang, Knut Liestøl, Marci E. Schaner, Ruth Holm, Dariush Etemadmoghadam, Kathryn Alsop, Pat Brown, Australian Ovarian Cancer Study Group, Gillian Mitchell, Sian Fereday, Anna DeFazio, David D. L. Bowtell, Gunnar B. Kristensen, Ole Christian Lingjærde, Anne-Lise Børresen-Dale

Conference Name

Abstract

Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies have suggested that extreme levels of genomic aberrations may be beneficial for the survival outcome for patients with specific tumour types. We investigated the extent of genomic instability in predominantly high-grade serous ovarian cancers (SOC) using two independent datasets, generated in Norway (n = 74) and Australia (n = 70), respectively. Genomic instability was quantified by the Total Aberration Index (TAI), a measure of the abundance and genomic size of copy number changes in a tumour. In the Norwegian cohort, patients with TAI above the median revealed significantly prolonged overall survival (p<0.001) and progression-free survival (p<0.05). In the Australian cohort, patients with above median TAI showed prolonged overall survival (p<0.05) and moderately, but not significantly, prolonged progression-free survival. Results were confirmed by univariate and multivariate Cox regression analyses with TAI as a continuous variable. Our results provide further evidence supporting an association between high level of genomic instability and prolonged survival of high-grade SOC patients, possibly as disturbed genome integrity may lead to increased sensitivity to chemotherapeutic agents.

School/Discipline

Dissertation Note

Provenance

Description

Martin K Oehler is a member of the Australian Ovarian Cancer Study Group

Access Status

Rights

© 2013 Baumbusch et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

License

Call number

Persistent link to this record